Hoth Therapeutics (NASDAQ:HOTH) Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Hoth Therapeutics (NASDAQ:HOTH) from a sell rating to a hold rating in a research note published on Saturday.

Separately, D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of Hoth Therapeutics in a research note on Tuesday, April 15th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Hoth Therapeutics has an average rating of “Buy” and an average price target of $4.00.

Hoth Therapeutics Stock Performance

Shares of HOTH stock opened at $0.93 on Friday. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $3.80. The company has a market capitalization of $12.28 million, a PE ratio of -0.70 and a beta of 0.53. The business’s fifty day moving average is $0.86 and its 200 day moving average is $1.00.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.07. On average, sell-side analysts forecast that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95,946 shares of the company’s stock after purchasing an additional 13,038 shares during the period. Geode Capital Management LLC owned 1.39% of Hoth Therapeutics worth $72,000 at the end of the most recent reporting period. 7.08% of the stock is owned by hedge funds and other institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.